Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil.

doi:10.1590/0037-8682-0279-2017

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil.

Revista da Sociedade Brasileira de Medicina Tropical - 1 Jan 2000

Lobato Cirley Maria de Oliveira, Balassiano Natalia, Hyppolito Elodie Bomfim, Sanchez-Lermen Rafaela Liz Pellegrim, Signorelli Izabelle Venturini, Nicacio Miguel Yasuo Tomita, Firmino Filho Alberto Pereira, Andrade Thais Guaraná de, Lima José Milton de Castro, Arruda Talita Amorim de, Coutinho Fernanda Schwanz, Araujo Everton Felipe do Vale, Esmeraldo Ticiana Mota, Cortez Erlon, Capeli Rafaela Lorenzon Aragão, Matos Melquior Brunno Mateus de, Pessoa Francisco Sérgio Rangel, Oliveira Hélder Cássio de, Arruda Érico Antônio Gomes de, Gonçalves Patrícia Lofêgo, Araújo Filho Antônio Haroldo, Esberard Eliane Bordalo Cathalá, Souto Francisco José Dutra

Abstract excerpt

INTRODUCTION: In 2013, combination therapy using peginterferon, ribavirin, and boceprevir or telaprevir was introduced to treat hepatitis C virus genotype 1 infection in Brazil. The effectiveness of this therapy in four Brazilian regions was evaluated. METHODS: Clinical and virological data were obtained from patients of public health institutions in five cities, including sustained virological response (SVR) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Protocols

Share to Drug Therapy, Combination

Share to Interferons

Share to Oligopeptides

Share to Proline

Share to Protease Inhibitors

Share to Ribavirin

Share to Sustained Virologic Response

Source

Open in PubMed

Identifiers

PMID: 29513836
DOI: 10.1590/0037-8682-0279-2017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil.PMID 29513836Read ↗

First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients.Semantic proximity Read ↗

Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.Semantic proximity Read ↗

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].Semantic proximity Read ↗

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.Semantic proximity Read ↗

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.Semantic proximity Read ↗

Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.Semantic proximity Read ↗

Hepatitis C therapy update.Semantic proximity Read ↗

Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.Semantic proximity Read ↗

Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.Semantic proximity Read ↗

The role of triple therapy in HCV genotype 1-experienced patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.